Startseite>>Signaling Pathways>> Immunology/Inflammation>> Complement System>>ADH-503

ADH-503 (Synonyms: (Z)-Leukadherin-1 choline)

Katalog-Nr.GC60040

ADH-503 ((Z)-Leukadherin-1-Cholin) ist ein oral aktiver und allosterischer CD11b-Agonist. ADH-503 fÜhrt zur Repolarisation tumorassoziierter Makrophagen, zur Verringerung der Anzahl tumorinfiltrierender immunsuppressiver myeloischer Zellen und verstÄrkt die Reaktionen dendritischer Zellen.

Products are for research use only. Not for human use. We do not sell to patients.

ADH-503 Chemische Struktur

Cas No.: 2055362-74-6

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
58,00 $
Auf Lager
5mg
51,00 $
Auf Lager
10mg
83,00 $
Auf Lager
50mg
232,00 $
Auf Lager
100mg
324,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses[1].

ADH-503 ((Z)-Leukadherin-1 choline; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b+ cells and subsets of CD11b+ monocytes, granulocytes, eosinophils, and macrophages[1].

ADH-503 ((Z)-Leukadherin-1 choline; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival[1]. ADH-503 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC0-t in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively[1]. Animal Model: KPC mice [p48-CRE/Lox-stop-Lox(LSL)-KrasG12D/p53flox/flox][1]

[1]. Panni RZ, et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci Transl Med. 2019 Jul 3;11(499).

Bewertungen

Review for ADH-503

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ADH-503

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.